Brief: Sienna Completes Maximal Use Safety Study Of SNA-120 In Patients With Itch Associated With Psoriasis

Sienna Biopharmaceuticals

24/07/2018 14:20

July 24 (Reuters) - Sienna Biopharmaceuticals Inc  SNNA.O :
    * SIENNA BIOPHARMACEUTICALS SUCCESSFULLY COMPLETES MAXIMAL
USE
SAFETY STUDY OF SNA-120 IN PATIENTS WITH ITCH ASSOCIATED WITH
PSORIASIS
    * SIENNA BIOPHARMACEUTICALS INC - PHASE 2B TOPLINE DATA
EXPECTED
IN Q1 OF 2019
    * SIENNA - NO DERMAL TOLERABILITY ISSUES, NO SUBJECT
DISCONTINUATIONS DUE TO AE & NO SEVERE AES OR SERIOUS AES IN
STUDY
    * SIENNA BIOPHARMACEUTICALS INC - SNA-120 WAS WELL TOLERATED
WITH
MINIMAL TO NO DETECTABLE SYSTEMIC EXPOSURE

Source text for Eikon:  ID:nGNX4jZ24 
Further company coverage:  SNNA.O 

 ((Reuters.Briefs@thomsonreuters.com;))